Enrique Caballé

In this real-world analysis from @incan, we study progression patterns in metastatic NSCLC treated with anti-PD-(L)1. doi.org/10.1016/j.ctar… Oligo-PD and acquired resistance are associated with better survival, suggesting that these patients may benefit from continued IO beyond progression and local ablative therapies. Systemic PD, primary resistance, and combined failure patterns indicate a worse prognosis, requiring timely switching to alternative systemic treatments. Integrating time to resistance, progression patterns, and lesion-level dynamics is important for refined risk stratification and personalized post-progression management strategies. @Ecaballep @maritza_rramos @DrLuisCM

We published in lung cancer a review of respiratory sarcopenia in the area of ​​thoracic oncology. doi.org/10.1016/j.lung… Respiratory sarcopenia is a clinically relevant but incompletely defined. A feasible, strength-first screening can identify patients who may require closer peri-operative attention. Imaging surrogates and diaphragm ultrasound provide additional contextual information when available. While reported associations with complications and survival are suggestive, they are uneven due to heterogeneity in definitions, thresholds, and protocols. Within enhanced recovery pathways, inspiratory muscle training can be considered a component of multimodal optimization for selected patients. We emphasize that careful, claims-disciplined use of RS metrics, as a complement to established risk tools and clinical judgment, is reasonable. Future priorities include harmonizing measurement protocols and deriving thoracic-specific thresholds to determine who benefits most and how best to deploy resources effectively. @detectoincan @incanMX @JordiRemon @MarisolNeumo @JennyTurcott @Ecaballep @LungCancerEu @AndresFCardonaz

@AMIMC8 @SMEOMX 17 colaboradores, 10 meses de trabajo. Libro ✅ 43 Congreso Nacional de Oncología 😊😊

We reported in @NatureComms, this phase 2 trial, the combination of alectinib and bevacizumab (ALEK-B) in patients with advanced ALK rearranged NSCLC from @incanMX, the 12-month PFS rate was 97.1% The 36-month PFS and OS rates were 64.2% and 87.9% respectively. The ORR was 100%, and the 36-month icPFS rate was 87.8%. Grade 3–4 adverse events occurred in 46.3% of patients, most commonly proteinuria and hepatotoxicity, QoL significantly improved from baseline at 12 months and was maintained through 36 months. These findings support the efficacy and safety of alectinib plus bevacizumab and justify further investigation in ALK-rearranged NSCLC. nature.com/articles/s4146… @AndresFCardonaZ @Ecaballep @LuisLara_M @JordiRemon

@josemarialucio @ogarrieta @YanHernandezP @maritza_rramos @RealCaesarCas @EuniceNu10

@Ecaballep @ogarrieta @YanHernandezP @maritza_rramos @RealCaesarCas @Ecaballep

link.springer.com/article/10.100… Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy @ogarrieta @YanHernandezP @maritza_rramos @josemarialucio @RealCaesarCas

Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country | JCO Global Oncology ascopubs.org/doi/10.1200/GO…

In this cohort, we included 446 NSCLC patients who underwent different NGS panels at the National Cancer Institute of Mexico, 65% had no history of smoking. PFS was significantly longer in patients with actionable mutations treated with targeted therapies (19.4m P.001) than in patients without actionable mutations (6.4m) or not treated with targeted therapies (6.6m). Similarly, OS was significantly longer in patients with actionable mutations treated with targeted therapies (89.7m P < .001) than in patients without actionable mutations (17.1m) or not treated with targeted therapies (22.3m). An important step toward improving the clinical outcomes of patients with NSCLC is to ensure wider access to broadmolecular testing and targeted therapies so that patients receive the most appropriate treatment. @Ecaballep @AndresFCardonaZ @UToracica ascopubs.org/doi/10.1200/GO…

#LungCancer is challenging enough – imagine facing it without access to essential tests or trtmts. For many #EGFR+ pts worldwide, this is reality. Tackling global health inequities means making diagnostics & targeted therapies accessible to all. jto.org/article/S1556-… @Ecaballep @ogarrieta

Lung cancer remains a global challenge, especially in LMICs with limited access to NSCLC molecular testing. A recent study reveals high EGFR mutation rates and low adherence to adjuvant therapy guidelines. Read our editorial for more insights. @ogarrieta jto.org/article/S1556-…

Been so lost without you all around me

Saudade de un café con miel

@paulina_juarezm 🥹🥹

☁️☁️🐈‍⬛🪽❤️☁️☁️🫶🏼🥺

@paulina_juarezm @CBSSports @Nickelodeon 👏👏 👏

@CBSSports @Nickelodeon @Ecaballep Back 5 yards!! 🏈

Dora the Explorer explaining a false start: "Where are we going?" *clap *clap *clap Boots: "Back 5 yards!" @Nickelodeon

@DanoFdez Queeee

Berlín 🤍

No digas nada porque está todo claro. ¿Te fijas, cariño, que a mí también me falló el atentando?

@paulina_juarezm 🐝 🩻

@Ecaballep Debe regresar a tórax! 🐝 🫁

🐝 💤 💤

@paulina_juarezm Conmigo 🐝

@Ecaballep Dónde está Peter ? 🐝

Wild heart surrender to me